Just had a quick look at the last report. in the section titled achievments, it says FDA submission is on target for Q4 - that's more slippage I'm afraid.
They also hint at a need to raise more capital, after having just raised 20m. Did they burn every cent they had before the last one?
The last cap raising was mooted as being the one that would carry the company to commercialisation. What's happened?
Sorry to be negative - have high hopes for this one, but the targets are beginning to slip - that's common with such stocks.
CXS Price at posting:
64.0¢ Sentiment: None Disclosure: Held